Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) |
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) |
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) |
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) |
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) |
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) |
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) |
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6747019 | TEVA WOMENS | Low dose estrogen interrupted hormone replacement therapy |
Mar, 2020
(4 years ago) | |
US7320970 | TEVA WOMENS | Low dose estrogen interrupted hormone replacement therapy |
Mar, 2020
(4 years ago) |
Drugs and Companies using ESTRADIOL; NORGESTIMATE ingredient
Market Authorisation Date: 22 October, 1999
Treatment: Hormone replacement; Prefest is indicated in women who have a uterus for the treatment of moderate to severe vasomotor symptoms associated with menopause; Treatment of vulvar and vaginal atrophy; Prev...
Dosage: TABLET;ORAL